RxDoctor Payments Data

Wing Kei Chiu, PA

Physician Assistant · Euless, TXNPI 1205596111

Payments from drug & device makers

$3,140in general payments, 2019–2025

Across 154 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$468
  • Otsuka America Pharmaceutical, Inc.$315
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
  • Axsome Therapeutics, Inc.$263
  • AbbVie$256
  • Alkermes, Inc.$249
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,140 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$17,402
Medicare patients
36
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine11$57,631
Invega SustennaPaliperidone Palmitate12$41,831
Lurasidone Hcl35$8,808
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$2,005
Aripiprazole49$1,741
Vilazodone Hcl17$1,194
Quetiapine Fumarate34$1,185
Bupropion XlBupropion Hcl49$1,092
Hydroxyzine Hcl47$1,084
Duloxetine Hcl39$962
Mirtazapine25$508
Sertraline Hcl52$372
Lithium Carbonate ErLithium Carbonate13$261
Venlafaxine Hcl ErVenlafaxine Hcl17$252
Trazodone Hcl41$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$42$57,63111 claims
Johnson & JohnsonInvega Sustenna$219$41,83112 claims
Almatica Pharma LLCSertraline Hcl$19$37252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Euless

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →